

**Supple Table 2. Baseline demographic, clinical, and laboratory data for type 2 diabetic patients showing a PAI-1 decrease or a PAI-1 increase after treatment with empagliflozin (10 mg/day)**

	PAI-1		<i>P</i> value
	Decrease	Increase	
N (M/F)	20 (10/10)	10 (6/4)	0.7089
Age (years)	58.6±12.9	56.0±12.0	0.6128
Body weight (kg)	71.3±18.0	70.6±23.0	0.9353
BMI (kg/m <sup>2</sup> )	27.5±5.9	26.7±5.8	0.7236
Waist circumference (cm)	97.8±10.2	96.6±18.0	0.8316
VFA (cm <sup>2</sup> )	105.9±48.2	108.6±59.2	0.8694
SBP (mmHg)	135.8±22.3	130.0±12.2	0.4719
FPG (mg/dl)	173.9±54.7	170.0±40.3	0.8491
HbA1c (%)	7.87±0.80	8.36±0.97	0.1609
LDL cholesterol (mg/dl)	91.7±25.1	97.6±25.6	0.5626
Triglyceride (mg/dl)	110.5 (76.5, 161.5)	108 (56, 146)	0.5862
HDL-cholesterol (mg/dl)	52.7±13.8	57.4±22.4	0.4832
RLP-cholesterol (mg/dl)	5.75 (2.93, 7.9)	4.5 (3.05, 8.65)	0.9539
ALT (U/L)	26.5 (13, 42)	42 (18, 122.5)	0.1863
GGT (U/L)	29 (22.3, 49.3)	28 (18.5, 270)	0.8622
Uric acid (mg/dl)	5.15±1.04	5.91±1.72	0.1484
Hematocrit (%)	42.8±3.8	43.4±4.3	0.7080

Platelets ( $\times 10^9/\text{mL}$ )	25.6 $\pm$ 6.1	22.0 $\pm$ 5.1	0.1377
eGFR (ml/min/1.73m <sup>2</sup> )	77.7 $\pm$ 16.7	79.0 $\pm$ 32.0	0.8877
PAI-1 (ng/ml)	42.5 (29.5, 56)	23 (9.9, 28.5)	0.0023
PAP ( $\mu\text{g/ml}$ )	0.5 (0.3, 0.8)	1 (0.65, 1.25)	0.0024
TAT (ng/ml)	2.1 (1.1, 3.85)	1.5 (1.05, 2.85)	0.4153
HMW adiponectin ( $\mu\text{g/ml}$ )	1.91 (1, 2.56)	1.66 (0.61, 8.83)	0.6353
Leptin (ng/ml)	15.4 (6.15, 25.6)	10.3 (6.95, 13.0)	0.3968
Metformin/DPP-4i/SU/TZD/Ins, <i>n</i>	9/12/10/3/6	6/6/4/2/4	0.9635
Statin use, <i>n</i> (%)	14 (70.0%)	8 (80.0%)	0.6821
ACEI+ARB/CCB/Diuretics/ $\beta$ -B, <i>n</i> (%)	9/6/2/4	4/2/1/1	0.9626

Data are the mean $\pm$ SD or the median and inter-quartile ranges.

BMI, body mass index; VFA, visceral fat area; FPG, fasting plasma glucose; Hb, hemoglobin; ; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant like lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT,  $\gamma$ -glutamyltranspeptidase; eGFR, estimated glomerular filtration; PAI-1, plasminogen activator inhibitor-1; PAP, plasmin- $\alpha$ 2-antiplasmin complex ; TAT, thrombin-antithrombin III complex ; HMW, high molecular weight; DPP-4i , dipeptidyl peptidase-4 inhibitors; SU, sulfonylurea; TZD, thiazolidinedine; Ins, insulin; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.